Miracell selected as a “Global Promising Company” by the Ministry of SMEs and Startups…
Possession of original technology for Smart Mcell stem cell extraction system
Stem cell specialist Miracell announced on the 21st that it has been selected as a promising company for the “2024 Global 1,000+ Small and Medium Enterprises Project,” hosted by the Ministry of SMEs and Startups.
This project is a national initiative that designates promising export SMEs that are entering the global market based on their technological prowess and innovation.
This system selects SMEs with high growth potential among those with exports exceeding $100,000 in the previous year and provides preferential overseas marketing and financing support from export support agencies.
For 2024, 473 companies were selected based on export volume, categorized into four categories: Global Promising, Growth, Strong, and Strong+.
Miracell was recognized for its contribution to increased exports and national economic development through its stem cell extraction system, “SMART M-CELL” and BmSC kit. In November of last year,
the Ministry of Trade, Industry and Energy designated Miracell a “Next Generation World-Class Product.”
Following its designation as a promising global small and medium-sized enterprise by the Public Procurement Service (PPS), Miracell has been highly evaluated by the government for its potential to lead the global market.
Founded in the medical industry in 1986, Miracell has been actively developing stem cell systems since 2007. It manufactures ready-to-use biological drugs,
and has directly registered new medical technologies using autologous stem cells for acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, through clinical research with renowned professors at university hospitals,
last year, it received approval for a new medical technology for its bone marrow stem cell injection treatment for knee osteoarthritis.
Smart Mcell & BmSC is a biosystem capable of extracting large quantities of stem cells. It separates and concentrates stem cells, growth factors, and total cells from a patient’s blood and bone marrow.
It boasts a cell viability rate of up to 99%. Smart M-Cell is a core therapeutic material in regenerative medicine, used in knee osteoarthritis treatment and anti-aging procedures at university hospitals and other hospitals nationwide.
Miracell has consistently achieved export success by participating in conferences such as the American Academy of Orthopaedic Surgeons (AAOS), the European Society of Sports Traumatology, Knee and Arthroscopy (ESSKA),
and the American Medical World Congress (AMWC) to promote Korea’s stem cell system.
As a result, SMART M-CELL has been adopted and used in hospitals in Europe, as well as in other countries, including Sweden, Austria, Greece, Italy, and Turkey.
Shin Hyun-soon, CEO of Miracell, stated, “Having been selected as a promising company in this global small and medium-sized enterprise project and given favorable conditions for exports,
we will further dedicate ourselves to promoting Korea’s outstanding regenerative biosystem to the global market.”
Reporter Lee Jeong-hee kunkang1983@naver.com
Source: Health Digest (http://m.ikunkang.com/news/articleView.html?idxno=40018)